ESTRACYT, also known by its generic name estramustine, is a chemotherapy medication primarily used in the treatment of prostate cancer. It operates as a unique combination of an estrogen hormone and a nitrogen mustard-derived alkylating agent. This dual mechanism allows ESTRACYT not only to interfere with the cancer cells' ability to grow and multiply by damaging their DNA, but also to exploit the hormone sensitivity of certain prostate cancers. By reducing testosterone levels and disrupting the cancer cells' environment, it can slow or halt the progression of the disease. ESTRACYT is typically administered in capsule form and is used in cases where the cancer has not responded to other treatments. Its use is associated with a range of potential side effects, reflecting its systemic impact on the body, and its administration is carefully monitored by healthcare professionals.